We learned from the site of the 2025 Innovative Drug High Quality Development Conference held today that various rare disease drugs were included in the 2025 medical insurance catalogue and the commercial insurance innovative drug catalogue. Among them, Fosun Pharmaceuticals' ruvometinib tablets entered the 2025 medical insurance catalogue, and Beihai Kangcheng's injectable veradidase beta entered the commercial insurance innovative drug catalogue. However, the first domestic vormololone oral suspension approved for the treatment of Duchenne muscular dystrophy under Shufang Pharmaceutical, which has both medical insurance and commercial insurance reports, did not appear on the list. Lovometinib tablets are the first and currently the only domestically produced original MEK1/2 inhibitor approved for the above indications. They are used to treat NF1-related plexiform neurofibromatosis in children and adolescents aged 2 years and above, and Langerhans cell histiocytosis and histiocytic tumors in adults. Injectable veraginase beta is the first domestically produced Gossetol replacement therapy and was approved for marketing in May of this year.

Zhitongcaijing · 2d ago
We learned from the site of the 2025 Innovative Drug High Quality Development Conference held today that various rare disease drugs were included in the 2025 medical insurance catalogue and the commercial insurance innovative drug catalogue. Among them, Fosun Pharmaceuticals' ruvometinib tablets entered the 2025 medical insurance catalogue, and Beihai Kangcheng's injectable veradidase beta entered the commercial insurance innovative drug catalogue. However, the first domestic vormololone oral suspension approved for the treatment of Duchenne muscular dystrophy under Shufang Pharmaceutical, which has both medical insurance and commercial insurance reports, did not appear on the list. Lovometinib tablets are the first and currently the only domestically produced original MEK1/2 inhibitor approved for the above indications. They are used to treat NF1-related plexiform neurofibromatosis in children and adolescents aged 2 years and above, and Langerhans cell histiocytosis and histiocytic tumors in adults. Injectable veraginase beta is the first domestically produced Gossetol replacement therapy and was approved for marketing in May of this year.